Novel Antibiotics and Emerging Resistance: In Vitro Activity of Five Antimicrobials Against Intensive Care Unit Isolates from a Turkish Tertiary Care Hospital

Read full text Summarise with VIRAT
Authors: Hüseyin Haydar Kutlu, Fatma Nur Akdoğan-Kittana, Betül Günaydın, Yekta Özkılıç
Cited by: 0
References: 27

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: The global spread of antibiotic resistance, particularly in carbapenem-resistant Gram-negative bacteria, has become a major public health concern. Recently developed antibiotics—ceftazidime-avibactam (CAZ-AVI), ceftolozane-tazobactam (TOL-TAZ), meropenem-vaborbactam (MER-VAB), eravacycline (ERV), and delafloxacin (DLX)—represent promising therapeutic alternatives. This study aimed to assess resistance patterns to these novel agents among Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa isolates from intensive care units (ICUs). Materials and Methods: Between January 2023 and December 2024, isolates obtained from ICU cultures at Uşak Training and Research Hospital were analyzed. Species identification was performed using the VITEK® 2 and VITEK® MS systems (bioMérieux, Marcy-l’Étoile, France). Antimicrobial susceptibility testing was conducted with the VITEK® 2 AST XN21 card (bioMérieux, Marcy-l’Étoile, France), while colistin (COL) susceptibility was determined by broth microdilution. Results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, and statistical analysis was performed using Pearson’s chi-square test (p

Fields of Study & Subjects

Antibiotic Resistance in Bacteria Antibiotic Use and Resistance Bacterial Identification and Susceptibility Testing

Publication details

Journal / source
Infectious Diseases and Clinical Microbiology
Volume
8
Issue
2
Pages
179–179
Publication date
30 March 2026
Language
EN